| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 13 Feb 2025 | 10 Feb 2025 |
| NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/02/2025 inter alia to consider and approve 1. To consider and approve Un-audited Financial Results for the quarter ended 31st December 2024 along with Limited Review Report and Statement of Asset and Liability thereof. 2. To consider and approve requests regarding from Mr. Nimish Bhishma Thakore Promoter / Promoter Group for reclassification from Promoter / Promoter Group into Public Category to Public Category in accordance with the Regulation 31A of SEBI (LODR) Regulation 2015. 3. Any other business with the permission of Chair. As per attachment. (As Per BSE Announcement dated on 13.02.2025) | ||
| Board Meeting | 14 Nov 2024 | 11 Nov 2024 |
| NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2024 inter alia to consider and approve As per attachment. As per attachment. (As per BSE Announcement dated on 14/11/2024) | ||
| Board Meeting | 25 Sep 2024 | 25 Sep 2024 |
| As per attachment. | ||
| Board Meeting | 14 Aug 2024 | 9 Aug 2024 |
| NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2024 inter alia to consider and approve As per attachment. As per attachment. (As Per Bse Announcement Dated on 14.08.2024) | ||
| Board Meeting | 29 May 2024 | 22 May 2024 |
| NORRIS MEDICINES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2024 inter alia to consider and approve 1. To approve the Standalone Audited Financial Results as per IND-AS along with Audited Report for the quarter and year ended on 31st March 2024. 2. To approve the Statement of Assets and Liabilities for the year ended March 31 2024. 3. Any other business with the permission of chair. 1. Approval of Audited Standalone Financial Results for the quarter and year ended March 31, 2024 as per Regulation 33 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. 2. Approval of statement of Assets and liabilities for the year ended March 31, 2024. 3. Also note that M/s.Bahedia & Associates, Statutory auditors of the Company have issued the Audit report for the financial year ended on March 31, 2024 with unmodified opinion pursuant to regulation 33(3)(d) of the SEBI(LODR), Regulations, 2015. Read less.. (As Per BSE Announcement Dated on 29.05.2024) | ||
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
